Thesis (Ph. D.)--University of Hong Kong, 2006. / Title proper from title frame. Also available in printed format.

Solid organ transplant has emerged over the last half century as an important treatment for solid organ failure. Management has matured dramatically over the past two decades with improvements in acute rejection, but long-term graft survival has improved very little and current treatment is limited by the side-effects and toxicities of immunosuppressive medications. Nanoparticle delivery of therapeutics, improving transport characteristics and decreasing systemic and local toxicity has emerged as a dynamic treatment modality, but little work has been done using nanoparticles in transplantation. Our research examined the use of CD4-targeted nanoparticles encapsulated with mycophenolic acid (MPA), a commonly used immunosuppressant in organ transplantation. This work is the first to examine antigen-specific targeting of nanoparticles in any transplant model. MPA-loaded particles show a slow and continuous release profile and biodistribution suggested retention in the spleen. Targeting of nanoparticles to CD4 T cells was suggested using ex vivo and in vitro flow cytometry. In the fully allogeneic MHCII mismatch BALB/C to C57BL/6 mice we found improved graft survival in the non-targeted MPA group and even greater graft survival in the CD4-targeted group. Targeted and non-targeted particle groups showed equal delay in rejection in the less immunogenic single MHC mismatch B6.H-2bm12 to C57BL/6 model that we showed to be CD4 dependent. In both models, graft survival times were increased over free drug and controls with roughly one thousand fold lower dose of drug in the nanoparticles as compared with free MPA. Consistent with these findings were decreased proliferation with targeted and non-targeted MPA-nanoparticles using in vitro and ex vivo mixed lymphocyte reactions. We postulated that the similar rejection times in targeted and non-targeted groups was due to dendritic cell (DC) involvement and we found active uptake of nanoparticles in DCs, a decrease in inflammatory cytokine production and a decrease in treated DCs ability to stimulate T cells via mixed lymphocyte reactions. Furthermore we found a possible mechanism in the DC interaction with T cells through the upregulation of the inhibiting co-stimulatory molecules B7-DC and B7-H1 on DCs treated with MPA-nanoparticles. We also found possible upregulation of CD4+CD25+ Foxp3 expressing Tregs which may serve to increase graft acceptance. These results explore the involvement of dendritic cells in the process of nanoparticle-induced graft acceptance and suggest the feasibility of using nanoparticle drug vectors in clinical transplant.

The location of the immunologic response to an allograft is not known with certainty. However, organized collections of T cells, B cells and antigen presenting cells have been found in peripheral tissue, in close proximity to organs undergoing rejection. It is hypothesized that this tertiary lymphoid tissue may be a location in which activation of lymphocytes can occur, leading to rejection of an allograft. We report here that in a splenectomized aly/aly mouse, which is devoid of secondary lymphoid organs and will normally fail to reject an allograft, the presence of tertiary lymphoid organs is associated with graft rejection. We additionally find that tertiary lymphoid organs can act as lymph nodes, and can support effector and memory allograft rejection responses. It is demonstrated that ectopic lymphoid tissue in aly/aly mice will support the multiplication and transformation of transferred naïve CD4 and CD8 T cells into cells that display phenotypic markers characteristic of effector and memory lymphocytes. These results demonstrate that ectopic lymphoid tissue is associated with the loss of immunologic ignorance and is sufficient to enable graft rejection. This suggests that allograft rejection may take place within ectopic lymphoid tissue, and suggests that techniques to interfere with the development of this tissue might offer a therapeutic approach to preserving organ allografts.

γδ T cells belong to the T cell lineage however they possess some innate like properties. γδ T cells recognize non-peptidic microbial and stress induced self antigens in a non-MHC restricted manner and are proposed to bridge the gap between innate and adaptive immunity. Dendritic epidermal T cells are a prototypic population of intraepithelial γδ T cells in murine skin. Found in the basal layer of epidermis in close contact with Langerhans cells and keratinocytes DETC facilitate vital immunological and physiological processes e.g. wound healing, homeostasis, tumour surveillance and regulation of inflammation. The purpose of this thesis was to elucidate whether γδ T cells and in particular DETC play a role in generation of adaptive immune responses to foreign cutaneous antigen (OVA) in the context of skin grafts. Skin grafting has long been established as a means to test cutaneous and epithelial immunity. To answer this question, γδ T cell knock-out mice (TCRδ-/-), transgenic K5mOva mice and a skin grafting model were used. It is shown in this study that in the absence of γδ in the skin and not in the circulation there is a lower rejection rate of OVA expressing skin grafts. This phenomenon is observed in both freshly placed and well healed grafts. To understand which part of the immune response is affected by the absence of γδ T cells the priming and effector phases of the immune response was examined in TCRδ-/- mice. The priming phase was studied using two approaches: the first approach was to test priming to maximal doses of subcutaneous antigen in conjunction with an adjuvant and the second approach involved testing priming to an antigen in the context of skin grafts (graft priming). Using ELISPOTs and CFSE proliferation assays we found that while administration of OVA in conjunction with an adjuvant (QuilA) via the subcutaneous route results in sufficient priming in γδ T cell knockout mice, cross priming to OVA in the context of - freshly placed and well healed skin grafts is impaired in TCRδ-/- mice. By immunizing TCRδ-/- mice prior to skin grafting or by transferring in vitro primed OT-I cells to RAG-/- mice grafted with K5mOVA or TCRδ-/-OVA skin it was shown that 100% of all OVA grafts are rejected regardless of presence or absence of γδ T cells, concluding that effector phase of the immune response is not affected in this model. The inability of DETC to perform the role of cross presentation leads to the hypothesis that DETC indirectly enhance this process by affecting professional antigen presenting cells (APC) of the skin. Based on the contribution of DETC to wound healing it was hypothesized that the migration of dendritic cells (DCs) from the skin grafts to the lymph nodes may be affected. When this hypothesis was tested using hapten sensitization and congenically marked skin grafts it was shown that migration of DCs from skin grafts is not affected by the absence of DETC. In another hypothesis the co-stimulatory markers CD40 and CD86 were examined on migrating DCs found in the skin draining lymph nodes of grafted mice and it was shown that expression levels of those molecules were lower on DCs from TCRδ-/- grafted mice compared to C57BL/6 control mice. In addition using cytometric bead array, we show that the cytokine milieu in TCRδ-/- skin and skin draining lymph nodes is different from that of wildtype C57 skin and this disparate cytokine profile may be contributing to the less efficient cross priming and graft rejection in TCRδ-/- mice.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

Thesis (M.Sc.)--University of Alberta, 2009. / A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science in Experimental Surgery, Department of Surgery, University of Alberta. Title from pdf file main screen (viewed on July 28, 2009). Includes bibliographical references.

Thesis (Ph.D.)--University of Alberta, 2009. / A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Experimental Surgery, Department of Surgery. Title from pdf file main screen (viewed on August 29, 2009). Includes bibliographical references.

Introdução: O papel do sistema HLA na evolução do transplante é indiscutível. Dados da literatura internacional e do nosso laboratório têm mostrado que este não é o único sistema envolvido nos processos de RMA (rejeição mediada por anticorpo) Esse fato é comprovado a partir da constatação de que transplantes realizados entre irmãos com total identidade HLA também são alvos da RMA. Entretanto, os alvos antigênicos desses anticorpos permanecem desconhecidos, dificultando assim o diagnostico e tratamento da RMA não-HLA. No transplante renal a presença desses anticorpos têm sido associada com anticorpos anti células endoteliais, células epiteliais tubulares, podocitos, células mesangiais e monócitos. Nosso objetivo neste estudo foi avaliar a presença e a relevância clínica de anticorpos contra a megalina, membro da família de receptores de LDL, expressa na membrana apical dos túbulos proximais, com importante papel na reabsorção de proteínas no rim. Métodos: Soros pré-transplante de 105 pacientes submetidos a transplante renal, realizado no Serviço de Transplante Renal do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (UTR-HC-FMUSP) foram testados por ELISA contra 2 peptídeos da megalina estudados e sintetizados em nosso laboratório. (convencionalmente chamados 18 e 19) Resultado: Não foi detectada a presença de anticorpos do isotipo IgG nas amostras prétransplante dos pacientes estudados. Entretanto, foi detectada a presença de anticorpos do isotipo IgM anti-peptídeo 18 em 33 (31,4%) amostras de soro e anti-peptídeo 19 em 23 (21,9%). Para avaliar a significância clinica desses anticorpos dividimos os pacientes em 2 grupos: pacientes com pelo menos 1 episodio de rejeição aguda (Grupo I) e pacientes sem rejeição (Grupo II) e observamos a distribuição dos pacientes positivos nos 2 grupos. O numero de pacientes com anticorpos anti-peptídeo 18 foi igualmente distribuída nos dois grupos. (12/42, 28,5% no Grupo I e 21/63, 33,3% no Grupo II p=ns). A maioria dos pacientes com anticorpos anti-peptídeo 19 pertenciam ao grupo I (17/42, 40,5% ; 6/63, 9,5% p=0,0003). Esta analise demonstrou uma boa correlação entre presença de anticorpos anti-peptídeo 19 no soro pré-transplante e rejeição. Conclusão: Nossos dados sugerem que anticorpos IgM anti-megalina no pré-transplante podem ser um fator de risco na rejeição do aloenxerto renal. É importante salientar que a nosso conhecimento este é o primeiro estudo envolvendo megalina e rejeição no transplante clínico. / Background. Preformed donor-specific human leukocyte antigen (HLA)- antibodies are accountable for the majority of antibody-mediated rejections (AMR). However, recipients of HLA identical kidneys can develop AMR implicating putative pathogenic antibodies that are directed against non-HLA antigens. Unknown immune targets and consecutive lack of detection methods make non-HLA AMR particularly difficult to diagnose and treat. In renal transplant rejection, the presence of antibodies to non-HLA has been associated with antibodies against endothelial cells, tubular epithelial cells, podocytes, mesangial cells and monocytes. The aim of this study was to evaluate the presence and clinical relevance of preformed antibodies against megalin, a member of the LDL receptor family, expressed on the apical membrane of proximal tubules. Megalin performs a central role in renal protein reabsorption. Methods. Pré-transplant sera of 105 recipients of kidney allograft transplanted at Serviço de Transplante Renal do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (STRHCFMUSP) were tested by enzyme-linked immunosorbent assay (ELISA) against 2 megalin-peptides (conventionally named 18 and 19) studied and synthetized in our laboratory. Results. Antibodies were not detected in pretranplant sera when tested for IgG isotype. However, in 33 (31,4%) sera we detected the presence of IgM antibodies to megalin-peptide18 and in 23 (21,9%) to megalin-peptide 19. To evaluate the clinical significance of these antibodies we divided the patients in 2 groups: Group I - 42 patients with at least one rejection episode during the first post-transplant year and Group II - 63 patients without any rejection episode and observed the distribution of positive patients in each of the 2 groups. Patients with megalin-peptide18 antibodies had the same distribution in both groups. (12/42, 28, 5% Group I and 21/63, 33,3% no Group II p=ns). However, patients with megalinpeptide19 antibodies were more frequent in group I. (17/42, 40,5% group I and 6/63, 9,5% group II p=0,0003). This analysis demonstrated a good correlation between preformed anti-megalin-peptide19 antibodies and allograft rejection Conclusion. Our data suggest that presence of IgM megalin antibodies before transplantation might be a risk factor for kidney allograft rejection. To our knowledge, this is the first study involving megalin and rejection in clinical transplantation.

Orientador: Sandra Cecilia Botelho Costa / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-10T19:48:47Z (GMT). No. of bitstreams: 1 Sampaio_AnaMaria_M.pdf: 6064318 bytes, checksum: 48e117e585e9ab62265d2b877c289d84 (MD5) Previous issue date: 2007 / Resumo: O Herpesvirus Humano 5 (HHV-5), Herpesvirus Humano 6 (HHV-6) e o Herpesvírus Humano 7 (HHV-7), são vírus universais pertencentes à subfamília betaherpesvirinae, e apresentam alta prevalência na população brasileira. Em adultos saudáveis, após infecção primária, esses vírus permanecem latentes, podendo ser reativados em um período de imunossupressão, como acontece em pacientes submetidos a transplantes, o que pode causar complicações graves, que vão desde rejeição de enxertos ao óbito. Esse estudo visou a monitorização da co-infecção pelo HHV-5, HHV-6 e HHV-7 em pacientes submetidos a transplante hepático no Hospital das Clínicas da UNICAMP e a correlação dos dados obtidos com o impacto clínico nesse grupo de pacientes para compreender melhor os aspectos que envolvem a infecção ativa pelo HHV-5, HHV-6, HHV-7 e suas inter-relações, utilizando técnicas laboratoriais que fazem diagnóstico precoce de infecção ativa, avaliação da terapia antiviral específica e prevenção da doença causada por esses vírus. Foram monitorizados 53 pacientes transplantados hepáticos através de testes de antigenemia e NESTED-PCR (N-PCR) em sangue periférico para a detecção do HHV-5, NESTED-PCR em sangue periférico para a detecção do HHV-6, NESTED-PCR em soro para detecção do HHV-7, que foram realizadas no pré-operatório e periodicamente no pós-operatório. Com essa metodologia 33/53 (62,3%) dos pacientes apresentaram infecção ativa por HHV-5, 21/53 (39,6%) por HHV-6 e 23/53 (43,4%) por HHV-7. A co-infecção ocorreu em 8/53 (15,1%) para HHV-5/HHV-6, e 5/53 (9,4%) para HHV-5/HHV-7, 2/53 (3,8%) por HHV-6/HHV-7, e 1/5 (1,9%) pelos três vírus estudados (HHV-5/HHV-6/HHV-7). Apresentaram infecções oportunistas 31/53 (58,5%) dos pacientes estudados, e destes 21/31 (39,6%) tiveram infecção ativa isoladamente por HHV-5, 14/31 (26,4%) tiveram infecção ativa isoladamente por HHV-6, e 11/31 (20,8%) tiveram infecção ativa isoladamente por HHV-7. Os resultados obtidos e os inúmeros estudos sobre o impacto clínico da detecção e tratamento desses betaherpsvírus em pacientes transplantados hepáticos mostram a importância de estudarmos sua prevalência, métodos diagnósticos e seu impacto clínico em nosso meio / Abstract: The human herpesvirus 5, human herpesvirus 6 e human herpesvirus 7 to the ß-herpesvirus subfamily of the Herpesviridae family. They show a hight prevalence in the population. Many times the infection remains assintomatic in healthy adults and can be reactivated from immunosuppression period especially after organ transplantation, as it happens to patients that underwent an organ transplantation, though it can cause several complication that are since allograft rejection to mortality. This study shows the monitoring of concurrent infection by HHV-5, HHV-6 and HHV-7 in patients that had been undergone to liver transplantation and the results among them with the clinic impact in this infection by HHV-5, HHV-6 and HHV-7 and its concurrent, using lab tecnique that present an early diagnostic of the active infection, management of specific therapy antiviral and prevention of the deseases caused by these virus. Fifty three patients posttranplanted were assisted though antigenemia and nested-pcr tests in peripheral blood to detection of HHV-5, and N-pcr in peripheral blood to detection of HHV-6 and N-pcr in serum to detection of HHV-7 that were done during before transplantation and always in the posttransplantation in these patients and its medical record analysis. The antigenemia to the HHV-6 and HHV-7 was (standard) for the first part of the test and the part is in the standard time. With this methodological, 62,3% of the patients showed active infection by HHV-5, 39,6% by HHV-6 and 43,4% by HHV-7, 15,1% of the patients, showed ( co-infection) HHV-5 and HHV-6, 9,4% by HHV-5/HHV-7, 3,8% by HHV-6/HHV-7 and 1,9% by three virus (HHV-5/HHV-6/HHV-7). 58,5% of the patients studied showed opportunistics infections, and 39,6% showed isoled active infection by HHV-5, (26,4%) showed isoled active infection by HHV-6 and (20,8%) showed isoled active infection by HHV-7. (58,5%) showed oportunites infection , 29% showed any kind of allograft rejection, 44,4% showed active infection by HHV-5, 44,4% showed active infection by HHV-6 and 33,3% by HHV-7. Human herpesvírus (HHV) 6 and 7 are novel members of the ß-herpesvirus family that maintain latency in the human host after primary infection. Reactivation from latency and/or increased degree of viral replication occurs during periods of immune dysfunction. The clinical effect of HHV-6 and HHV-7 reactivation in recipients of liver transplats is now being reconized. A gronving body of evidence suggests that the more important effect of HHV-6 and HHV-7 reactivation on the outcomes of liver transplantation may be mediated indirectly by their interactions with the other ß-herpesvirus - cytomegalovirus (HHV-5) we conducted a prospective study in fifthy three liver transplant patients to detect active infection by HHV-5, 6 and 7, using Nested PCR and antigenemia tests. Active infection with HHV-5 was detected in 62,3% by HHV-6 in 39,6% and 43,4% by HHV-7. Co- infection by HHV-5/HHV-6 occured in 15,1% of the patients, by HHV-5/HHV-7 in 9,4%, by HHV-6/HHV-7 in 3,8% and by HV-5/HHV-6/HHV-7 in 1,9%. Fivety eigth percent of the patients studied showed opportunistics infections, of this 39,6% had isolated active infection by HHV-5, 26,4% isolated active infection by HHV-6 and 20,8% isolated active infection by HHV-7. In conclusion, HHV-5, HHV-6 and HHV-7 active infection, are frequent in liver transplant patients and early diagnose to prevent clinical impact are necessary / Mestrado / Mestre em Farmacologia

INTRODUÇÃO: As moléculas HLA são os principais alvos da rejeição nos transplantes de órgãos sólidos. A influência dos anticorpos anti-HLA pré-formados e da compatibilidade HLA no transplante de fígado ainda não está bem definida. A maioria dos transplantes é realizada sem a pesquisa de anticorpos anti-HLA pré-formados e sem pareamento HLA. OBJETIVOS: Avaliar as associações dos anticorpos anti-HLA pré-formados e da compatibilidade HLA à rejeição celular aguda (RCA) em até 90 dias após o transplante. MÉTODOS: Coorte prospectiva de transplantes de fígado ABO compatíveis/idênticos realizados entre janeiro de 2012 e dezembro de 2013. Enxertos que sobreviveram além de 4 dias foram incluídos. A pesquisa de anticorpos anti-HLA classes I e II foram realizadas por meio de ensaios de fase sólida (LABScreen® Mixed e LABScreen® Single Antigen). MFI (Mean Fluorescence Intensity) >= 1.000 foi onsiderado omo positi o para anticorpos anti-HLA. Tipificação HLA-A, B e DR, de receptores e doadores foi feita por meio de PCR (Polymerase Chain Reaction). Conforme o número de alelos HLA incompatíveis, os transplantes foram classificados em compatíveis (0-3 incompatibilidades) e incompatíveis (4-6 incompatibilidades). Apenas episódios de RCA comprovados por biópsia, associados a alterações das provas hepáticas, foram considerados. O critério Banff foi utilizado para diagnóstico e os episódios foram estratificados em leves, moderados e graves. Modelos de regressão de Cox foram realizados e as razões de risco (RR) associadas foram determinadas. Sobrevidas livres de RCA foram obtidas por meio do estimador de Kaplan Meier e comparadas entre os grupos pelo teste log-rank. RESULTADOS: Cento e vinte e nove transplantes foram analisados. Incidência global de RCA em 90 dias foi de 14,7%. A pesquisa de anticorpos anti-HLA pré-formados foi considerada positiva em 35,6% dos transplantes. Em relação à compatibilidade HLA, 91,5% dos transplantes foram classificados como incompatíveis. A sensibilização para anticorpos anti-HLA foi associada a um risco aumentado de RCA (RR=4,3; IC 95%=1,3 - 13,5; p=0,012). De acordo com a classe do anticorpo, observamos que a classe II foi associada a um risco aumentado de RCA (RR=56,4; IC 95%= 4,5 - 709,6; p=0,002). Para anticorpos classe I, foi observada associação marginalmente significante (RR=2,77; IC 95%=0,8 - 8,8; p= 0,08). Uma melhor compatibilidade HLA não foi associada a um risco reduzido de RCA (RR= 0,9; IC 95%=0,2-4; p=0,89). CONCLUSÕES: O presente estudo mostrou que a sensibilização para anticorpos anti-HLA pré-formados om I >= 1.000 está asso iada a um risco aumentado de rejeição celular aguda precoce no transplante de fígado. Anticorpos classe II foram também associados a um risco aumentado de RCA e anticorpos classe I foram tendência. A melhor compatibilidade HLA não foi associada a um risco reduzido de RCA neste estudo. A presença de sensibilização para anticorpos anti-HLA pré-formados poderia servir como marcador de imunorreatividade aumentada contra os enxertos. Isso permitiria ajustes individualizados de imunossupressão / INTRODUCTION: Human leucocyte antigens (HLA) molecules are the main targets of rejection in solid organ transplantation. Significance of anti-HLA preformed antibodies and HLA compatibility remains unclear in liver transplantation. Majority of liver transplants are performed without assessment of preformed anti-HLA antibodies and HLA-matching. OBJECTIVES: Evaluate associations of preformed anti-HLA antibodies and HLA compatibility with acute cellular rejection (ACR) in the first 90 days after transplantation. METHODS: Prospective cohort of ABO-identical/compatible liver transplants between January 2012 and December 2013. Grafts that survived more than 4 days were included. Anti-HLA class I and II antibodies were determined by solid phase assays (LABScreen® Mixed and LABScreen® ingle Antigen). A mean fluores en e intensity ( I) >= 1.000 was considered as positive for anti-HLA antibodies. Recipients and donors HLA typing for HLA-A, B and DR were performed using polymerase chain reaction (PCR) assays. According to HLA mismatches (MM), transplants were divided in compatible (0-3 MM) and incompatible (4-6 MM). Only biopsy proven ACR episodes, associated with abnormal liver tests, were considered. Banff criteria was used for diagnosis of ACR and episodes were graded as mild, moderate and severe. Cox proportional hazards models were performed and associated hazard ratios (HR) were determined. Free ACR rates were estimated with Kaplan-Meier analysis and were compared between groups with the log-tank test. RESULTS: One hundred twenty nine transplants were analyzed. Overall incidence of ACR was 14.7% in 90 days. Assessment of anti-HLA pre-formed antibodies was considered positive in 35.6% of transplants. Regarding HLA compatibility, 91.5% were considered incompatible. Anti-HLA antibodies sensitization was associated with an increased risk of ACR (HR= 4.3; CI 95%=1,3 - 13,5; p=0.012). According to class of antibody, we could observe that class II was associated with an increased risk of ACR (HR=56.4; CI 95%= 4.5 - 709.6; p=0.002). Class I antibodies were considered tendency to increased risk of ACR (HR=2.7; CI 95%= 0.8 - 8.8; p=0,08). A better HLA compatibility was not associated with a lower risk of ACR (HR=0.9; CI 95%=0.2-3.8 p=0.89). CONCLUSIONS: The present study indicates that preformed anti-HLA antibodies with I >= 1.000 are associated with an increased risk of early ACR rejection in liver transplantation. Class II antibodies were also associated with an increased risk of ACR. Class I antibodies were considered tendency. HLA matching had no influence on early acute cellular rejection on this study. Anti-HLA antibodies sensitization could serve as a marker of increased immunoreactivity to the graft. It would serve for tailored immunosuppression